Changes in Hong Kong stocks | Alibaba Health (00241) fell more than 3%, and the company faced multiple factors. Institutions say its profit growth prospects are weak

The Zhitong Finance App learned that Ali Health (00241) fell by more than 3%. As of press release, it was down 3.07% to HK$2.84, with a turnover of HK$291 million.

UBS released a research report stating that the target price of Ali Health was lowered from HK$3.1 to HK$2.8 to maintain the “sale and sale” rating; the new target price is based on 17 times adjusted profit per share for the 2028 fiscal year. Previously, it was 19 times, slightly lower than the Internet medical industry average, to reflect the company's weak profit growth prospects. The bank said it is currently forecasting a 7-10% revenue increase for the 2027 fiscal year, lower than the 10-15% forecast, which mainly reflects the challenges faced by the industry, slowing the growth of the health products and medical device business, and the company's reduction in price discounts.

CICC pointed out that during the 1H27FY period, the bank observed stricter regulations on overseas health products, and sales of industry products were generally under pressure. Judging that the company's health products category was also negatively affected. However, considering that the overall level of online development of original research drugs and innovative drugs continues to increase, and the company is also continuously increasing cooperation in the field of innovative drugs, CICC expects that the company's drug category may continue to grow strongly in the first half of the fiscal year.